Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CVS CVS Health	$67.79 +1.0%	$62.12	$43.56 ▼ $79.98	$85.46B	0.54	11.59 million shs	7.46 million shs
MRNA Moderna	$28.35 -8.9%	$34.72	$26.22 ▼ $170.47	$10.96B	1.86	6.87 million shs	20.44 million shs
PFE Pfizer	$25.36 +0.6%	$26.06	$24.48 ▼ $31.54	$143.80B	0.61	39.09 million shs	53.46 million shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CVS CVS Health	0.00%	-0.14%	+1.94%	+52.77%	-15.84%
MRNA Moderna	0.00%	-4.72%	+0.52%	-20.98%	-70.80%
PFE Pfizer	0.00%	-3.83%	-4.65%	-4.61%	-9.19%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CVS CVS Health	4.9115 of 5 stars	2.5	4.0	3.3	3.9	3.0	3.3	3.1
MRNA Moderna	4.1962 of 5 stars	4.0	1.0	0.0	4.6	2.1	2.5	0.6
PFE Pfizer	4.9865 of 5 stars	3.3	3.0	4.2	4.2	3.3	3.3	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CVS CVS Health	2.90	Moderate Buy	$70.41	3.87% Upside
MRNA Moderna	2.04	Hold	$59.00	108.11% Upside
PFE Pfizer	2.63	Moderate Buy	$31.92	25.90% Upside

Current Analyst Ratings Breakdown

Latest CVS, MRNA, and PFE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/21/2025	CVS CVS Health	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$72.00 ➝ $74.00
3/21/2025	MRNA Moderna	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$40.00 ➝ $33.00
3/18/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/13/2025	MRNA Moderna	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$40.00
3/12/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/10/2025	PFE Pfizer	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
2/19/2025	MRNA Moderna	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$96.00 ➝ $78.00
2/18/2025	CVS CVS Health	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$77.00
2/18/2025	CVS CVS Health	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$80.00 ➝ $81.00
2/18/2025	MRNA Moderna	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform	$40.00 ➝ $40.00
2/18/2025	MRNA Moderna	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$111.00 ➝ $45.00

(Data available from 3/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CVS CVS Health	$372.81B	0.23	$9.47 per share	7.16	$60.06 per share	1.13
MRNA Moderna	$3.20B	3.43	N/A	N/A	$28.33 per share	1.00
PFE Pfizer	$63.63B	2.26	$3.97 per share	6.38	$15.81 per share	1.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CVS CVS Health	$4.61B	$3.66	18.52	10.01	0.98	1.24%	9.11%	2.71%	4/29/2025 (Estimated)
MRNA Moderna	-$3.56B	-$9.28	N/A	N/A	N/A	-110.04%	-28.74%	-21.83%	5/1/2025 (Estimated)
PFE Pfizer	$8.03B	$1.41	17.98	8.37	0.64	12.62%	19.47%	8.09%	4/29/2025 (Estimated)

Latest CVS, MRNA, and PFE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
2/12/2025	Q4 2024	CVS CVS Health	$0.89	$1.19	+$0.30	$1.30	$96.90 billion	N/A
2/4/2025	Q4 2024	PFE Pfizer	$0.48	$0.63	+$0.15	$0.07	$17.26 billion	$17.76 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CVS CVS Health	$2.66	3.92%	+9.97%	72.68%	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	6.78%	+2.50%	121.99%	16 Years

Latest CVS, MRNA, and PFE Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
3/20/2025	CVS CVS Health	quarterly	$0.6650	3.89%	4/22/2025	4/22/2025	5/1/2025
1/3/2025	CVS CVS Health	quarterly	$0.6650	6.02%	1/23/2025	1/23/2025	2/3/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CVS CVS Health	0.80	0.81	0.60
MRNA Moderna	N/A	3.67	3.62
PFE Pfizer	0.63	1.00	0.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CVS CVS Health	80.66%
MRNA Moderna	75.33%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
CVS CVS Health	0.24%
MRNA Moderna	11.00%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CVS CVS Health	300,000	1.26 billion	1.26 billion	Optionable
MRNA Moderna	3,900	386.62 million	324.40 million	Optionable
PFE Pfizer	83,000	5.67 billion	5.66 billion	Optionable

CVS, MRNA, and PFE Headlines

Recent News About These Companies

Pfizer (NYSE:PFE) Shares Down 0.8% - What's Next?

March 31 at 2:24 PM | marketbeat.com

Vaccine stocks fall after key FDA official resigns in protest of RFK Jr.

March 31 at 10:13 AM | cnbc.com

March 31 at 10:05 AM | zacks.com

Pfizer: Looks Better Than Most, But I Can't Eat Relative Returns

March 31 at 8:34 AM | seekingalpha.com

Biotech stocks tumble on reports FDA's top vaccine regulator to leave

March 31 at 7:25 AM | reuters.com

HighPoint Advisor Group LLC Lowers Position in Pfizer Inc. (NYSE:PFE)

March 31 at 7:19 AM | marketbeat.com

B. Metzler seel. Sohn & Co. AG Has $10.20 Million Holdings in Pfizer Inc. (NYSE:PFE)

March 31 at 6:58 AM | marketbeat.com

Bedell Frazier Investment Counselling LLC Takes $618,000 Position in Pfizer Inc. (NYSE:PFE)

March 31 at 6:31 AM | marketbeat.com

Edmond DE Rothschild Holding S.A. Decreases Stock Holdings in Pfizer Inc. (NYSE:PFE)

March 31 at 6:22 AM | marketbeat.com

AIA Group Ltd Trims Stock Position in Pfizer Inc. (NYSE:PFE)

March 31 at 6:01 AM | marketbeat.com

Wellington Management Group LLP Sells 23,736,431 Shares of Pfizer Inc. (NYSE:PFE)

March 31 at 5:53 AM | marketbeat.com

Skba Capital Management LLC Boosts Holdings in Pfizer Inc. (NYSE:PFE)

March 31 at 5:52 AM | marketbeat.com

RWA Wealth Partners LLC Sells 393,531 Shares of Pfizer Inc. (NYSE:PFE)

March 31 at 5:17 AM | marketbeat.com

Pfizer’s Strong Financial Performance and Strategic Developments Drive Buy Rating

March 31 at 4:00 AM | tipranks.com

Pfizer (PFE) Navigates Challenges with Strong Performance Amid 2025 Market Pressures

March 30 at 6:57 PM | gurufocus.com

Pfizer Inc. (PFE): Among Blue Chip Stocks to Invest in at 52-Week Lows

March 30 at 9:42 AM | insidermonkey.com

Bcwm LLC Invests $4.26 Million in Pfizer Inc. (NYSE:PFE)

March 30 at 6:58 AM | marketbeat.com

Walled Lake Planning & Wealth Management LLC Lowers Stake in Pfizer Inc. (NYSE:PFE)

March 30 at 6:57 AM | marketbeat.com

California Public Employees Retirement System Lowers Stock Holdings in Pfizer Inc. (NYSE:PFE)

March 30 at 6:23 AM | marketbeat.com

Life Planning Partners Inc Invests $893,000 in Pfizer Inc. (NYSE:PFE)

March 30 at 6:23 AM | marketbeat.com

Schroder Investment Management Group Raises Stake in Pfizer Inc. (NYSE:PFE)

March 30 at 5:55 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Warren Buffett Swaps VOO for This Reliable Dividend Stock
By Sarah Horvath | March 7, 2025
View Warren Buffett Swaps VOO for This Reliable Dividend Stock
NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
By Thomas Hughes | March 12, 2025
View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
By Jeffrey Neal Johnson | March 21, 2025
View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
4 Healthcare Stocks With Massive Gains—and More to Come
By Sarah Horvath | March 29, 2025
View 4 Healthcare Stocks With Massive Gains—and More to Come
Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares
By Jea Yu | March 11, 2025
View Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares

CVS, MRNA, and PFE Company Descriptions

CVS Health NYSE:CVS

$67.79 +0.65 (+0.96%)

Closing price 03:59 PM Eastern

Extended Trading

$67.46 -0.32 (-0.47%)

As of 06:34 PM Eastern

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Health Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, specialty and mail order pharmacy, clinical, disease management, and medical spend management services. It serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, CMS, plans offered on public health insurance, and other sponsors of health benefit plans. The Pharmacy & Consumer Wellness segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. It operates online retail pharmacy websites, LTC pharmacies and on-site pharmacies, retail specialty pharmacy stores, compounding pharmacies and branches for infusion and enteral nutrition services. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was incorporated in 1996 and is headquartered in Woonsocket, Rhode Island.

Moderna NASDAQ:MRNA

$28.35 -2.77 (-8.90%)

Closing price 04:00 PM Eastern

Extended Trading

$28.42 +0.07 (+0.25%)

As of 06:43 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Pfizer NYSE:PFE

$25.36 +0.15 (+0.58%)

Closing price 03:59 PM Eastern

Extended Trading

$25.30 -0.06 (-0.24%)

As of 06:44 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time